MicroRNA expression can be a promising strategy for the detection of barrett's esophagus: A pilot study

Clinical and Translational Gastroenterology

Volumn 5, Issue 12, 2014, Pages

  Bansal, Ajay ^a,b   Hong, Xiaoman ^a   Lee, In Hee ^c   Krishnadath, Kausilia K ^d   Mathur, Sharad C ^b,e   Gunewardena, Sumedha ^a   Rastogi, Amit ^a,b   Sharma, Prateek ^a,b   Christenson, Lane K ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 192 5P; MICRORNA 194 5P; MICRORNA 215 5P; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BARRETT ESOPHAGUS; COHORT ANALYSIS; COLUMNAR EPITHELIUM; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION; HUMAN; INTESTINE METAPLASIA; LARGE INTESTINE; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE; STOMACH;

EID: 84927921155     PISSN: None     EISSN: 2155384X     Source Type: Journal    
DOI: 10.1038/ctg.2014.17     Document Type: Article

References (49)

1. Shaheen NJ.What is behind the remarkable increase in esophageal adenocarcinoma? Am J Gastroenterol 2014; 109: 345-347.
2. Dubecz A, Gall I, Solymosi N et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J Thorac Oncol 2012; 7: 443-447.
3. Cen P, Banki F, Cheng L et al. Changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States. Ann Surg Oncol 2012; 19: 1685-1691.
4. Prasad GA, Wu TT, Wigle DA et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology 2009; 137: 815-823.
5. Corley DA, Levin TR, Habel LA et al. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633-640.
6. Shaheen NJ, Hur C. Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus. Gastroenterology 2013; 145: 273-276.
7. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. Gastroenterology 2011; 140: 1084-1091.
8. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788-797.
9. Sharma P, Falk GW, Weston AP et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572.
10. Kadri SR, Lao-Sirieix P, O'Donovan M et al. Acceptability and accuracy of a nonendoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010; 341: c4372.
11. Liu N, Chen NY, Cui RX et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 2012; 13: 633-641.
12. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
13. Wang S, Wang L, Bayaxi N et al. A microRNA panel to discriminate carcinomas from high-grade intraepithelial neoplasms in colonoscopy biopsy tissue. Gut 2013; 62: 280-289.
14. Cortez MA, Bueso-Ramos C, Ferdin J et al. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nature reviews. Clin Oncol 2011; 8: 467-477.
15. Fassan M, Volinia S, Palatini J et al. MicroRNA Expression Profiling in the Histological Subtypes of Barrett's Metaplasia. Clin Transl Gastroenterol 2013; 4: e34.
16. Luzna P, Gregar J, Uberall I et al. Changes of microRNAs-192, 196a and 203 correlate with Barrett's esophagus diagnosis and its progression compared to normal healthy individuals. Diagn Pathol 2011; 6: 114.
17. Streppel MM, Pai S, Campbell NR et al. MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1. Clin Cancer Res 2013; 19: 4067-4078.
18. Garman KS, Owzar K, Hauser ER et al. MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer. Dig Dis Sci 2013; 58: 3178-3188.
19. Leidner RS, Ravi L, Leahy P et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 2012; 51: 473-479.
20. Bansal A, Lee IH, Hong X et al. Discovery and validation of Barrett's esophagus MicroRNA transcriptome by next generation sequencing. PLoS One 2013; 8: e54240.
21. Ribeiro-dos-Santos A, Khayat AS, Silva A et al. Ultra-deep sequencing reveals the microRNA expression pattern of the human stomach. PLoS One 2010; 5: e13205.
22. McKenna LB, Schug J, Vourekas A et al. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010; 139: 1654-1664; 1664 e1.
23. Locke GR, Talley NJ, Weaver AL et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 539-547.
24. Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392-1399.
25. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 2001; 32: 368-378.
26. Lao-Sirieix P, Boussioutas A, Kadri SR et al. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic. Gut 2009; 58: 1451-1459.
27. Efron BT, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall, Inc: New York. 1993.
28. Steyerberg EW, Harrell FE Jr., Borsboom GJ et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001; 54: 774-781.
29. Berezikov E. Evolution of microRNA diversity and regulation in animals. Nat Rev Genet 2011; 12: 846-860.
30. Odze R, Goldblum JR. Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. 2nd edition. Philadelphia: Elsiever, 2009.
31. Lavery DL, Nicholson AM, Poulsom R et al. The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands. Gut 2014; 63: 1854-1863.
32. Lao-Sirieix P, Fitzgerald RC. Screening for oesophageal cancer. Nature reviews. Clin Oncol 2012; 9: 278-287.
33. Stoltey J, Reeba H, Ullah N et al. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2007; 25: 83-91.
34. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482: 347-355.
35. Xu E, Gu J, Hawk ET et al. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 2013; 34: 2750-2756.
36. Dupont HL. Diagnosis and management of Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11: 1216-1223; quiz e73.
37. Bizouarn F. Clinical applications using digital PCR. Methods Mol Biol 2014; 1160: 189-214.
38. Mari L, Milano F, Parikh K et al. A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia. Cell Rep 2014; 7: 1197-1210.
39. Khella HW, Bakhet M, Allo G et al. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 2013; 34: 2231-2239.
40. Braun CJ, Zhang X, Savelyeva I et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008; 68: 10094-10104.
41. Pichiorri F, Suh SS, Rocci A et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18: 367-381.
42. Matsuzaki J, Suzuki H, Tsugawa H et al. Bile acids increase levels of microRNAs 221 and 222, leading to degradation of CDX2 during esophageal carcinogenesis. Gastroenterology 2013; 145: 1300-1311.
43. Bostrom P, Frisen J. New cells in old hearts. N Engl J Med 2013; 368: 1358-1360.
44. Matsuzaki J, Suzuki H. MicroRNAs in Barrett's esophagus: future prospects. Front Genet 2014; 5: 69.
45. Jones R, Junghard O, Dent J et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009; 30: 1030-1038.
46. Shaw MJ, Talley NJ, Beebe TJ et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52-57.
47. Suzuki H, Matsuzaki J, Okada S et al. Validation of the GerdQ questionnaire for the management of gastro-oesophageal reflux disease in Japan. United European Gastroenterol J 2013; 1: 175-183.
48. Sharma P, Wani S, Bansal A et al. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology 2007; 133: 454-464; quiz 674.
49. Balasubramanian G, Singh M, Gupta N et al. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol 2012; 107: 1655-1661.